Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297727 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL30910287 | 1.00 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL2991878 | 0.78 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL2991880 | 0.78 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL42674 | 0.77 | TP53 (0.38) | CA2CA1MMP1MMP2MME | |
| SCHEMBL42677 | 0.77 | TP53 (0.38) | CA2CA1MMP1MMP2MME | |
| SCHEMBL23260544 | 0.74 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL43381 | 0.74 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL43380 | 0.74 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL584507 | 0.74 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1CA2CA1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215123-B2 | Cordycepin-based derivatized compound with anti-tumor effect | NANJING TECH UNIVERSITY (CN) | 2025-02-04 | — | — | US | disclosed |
| US-20240116976-A1 | CORDYCEPIN-BASED DERIVATIZED COMPOUND WITH ANTI-TUMOR EFFECT | NANJING TECH UNIVERSITY (CN) | 2024-04-11 | — | — | US | disclosed |
| US-6951927-B2 | Proteins with integrin-like activity | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-10-04 | — | — | US | disclosed |
| US-6746853-B1 | USED IN THE TREATMENT OF INSULIN RELATED DISORDERS SUCH AS TYPE 1 DIABETES AND TYPE 2 DIABETES | XENCOR, INC. | 2004-06-08 | — | — | US | disclosed |
| US-6682923-B1 | NON-NATURALLY OCCURRING XYLANASE ACTIVITY (XA) PROTEIN; BLEACHING AGENT COMPRISING AS AN ACTIVE INGREDIENT AN XA PROTEIN IN THE BLEACHING PROCESS OF PULP AND IN THE FOOD AND ANIMAL FEED INDUSTRY | XENCOR | 2004-01-27 | — | — | US | disclosed |
| WO-2002038746-A9 | NOVEL THERMOSTABLE ALKALIPHILIC XYLANASE | XENCOR INC (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030054440-A1 | Novel proteins with integrin-like activity | CENTER FOR BLOOD RESEARCH | 2003-03-20 | — | — | US | disclosed |
| US-6514729-B1 | A non-naturally occurring protein with amino acid substitutions; Exhibits biological activity of human protein; Antiviral agent | XENCOR, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2000068396-A9 | BACILLUS CIRCULANS XYLANASE MUTANTS | XENCOR INC (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002038746-A2 | NOVEL THERMOSTABLE ALKALIPHILIC XYLANASE | XENCOR (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2000068387-A9 | NUCLEIC ACIDS AND PROTEINS WITH INTERFERON-BETA ACTIVITY | XENCOR INC (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-1183359-A2 | NUCLEIC ACIDS AND PROTEINS WITH INTERFERON-BETA ACTIVITY | Xencor Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1179075-A2 | BACILLUS CIRCULANS XYLANASE MUTANTS | Xencor, Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2002004521-A2 | PROTEINS WITH INTEGRIN-LIKE ACTIVITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2000069901-A2 | PROTEINS WITH INSULIN-LIKE ACTIVITY USEFUL IN THE TREATMENT OF DIABETES | XENCOR, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000068387-A2 | NUCLEIC ACIDS AND PROTEINS WITH INTERFERON-BETA ACTIVITY | XENCOR, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000068396-A2 | BACILLUS CIRCULANS XYLANASE MUTANTS | XENCOR, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215123-B2 | Cordycepin-based derivatized compound with anti-tumor effect | RNASE1, MCL1, DCK | ALDH1A1 2406/4885L3MBTL1 2654/4885CA2 3072/4885 |
| US-20240116976-A1 | CORDYCEPIN-BASED DERIVATIZED COMPOUND WITH ANTI-TUMOR EFFECT | RNASE1, MCL1, DCK | ALDH1A1 2406/4885L3MBTL1 2654/4885CA2 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.